Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells $756,500.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 50,000 shares of CeriBell stock in a transaction on Friday, November 21st. The shares were sold at an average price of $15.13, for a total value of $756,500.00. Following the completion of the transaction, the chief executive officer owned 798,135 shares of the company’s stock, valued at approximately $12,075,782.55. The trade was a 5.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

CeriBell Price Performance

Shares of CeriBell stock traded up $1.34 during trading on Tuesday, reaching $17.35. The company’s stock had a trading volume of 679,211 shares, compared to its average volume of 297,570. CeriBell, Inc. has a one year low of $10.01 and a one year high of $32.75. The stock has a 50-day moving average price of $12.42 and a two-hundred day moving average price of $14.34. The stock has a market capitalization of $643.69 million and a P/E ratio of -11.49. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. The business had revenue of $22.59 million during the quarter, compared to analyst estimates of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. CeriBell has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. TD Cowen lowered their target price on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Raymond James Financial began coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.17.

Institutional Trading of CeriBell

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its stake in shares of CeriBell by 42.3% in the first quarter. Bank of New York Mellon Corp now owns 34,542 shares of the company’s stock valued at $664,000 after buying an additional 10,268 shares during the period. New York State Common Retirement Fund bought a new position in CeriBell in the 1st quarter worth approximately $67,000. KLP Kapitalforvaltning AS purchased a new position in CeriBell in the 1st quarter valued at approximately $36,000. Federated Hermes Inc. raised its holdings in CeriBell by 111.3% during the 1st quarter. Federated Hermes Inc. now owns 786,751 shares of the company’s stock valued at $15,113,000 after acquiring an additional 414,500 shares during the period. Finally, Deutsche Bank AG boosted its holdings in shares of CeriBell by 0.4% in the first quarter. Deutsche Bank AG now owns 231,629 shares of the company’s stock worth $4,450,000 after acquiring an additional 842 shares during the period.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.